Pirkko Matilla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pirkko Matilla has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Aikaterini Spantidaki
Radboud University Medical Center, Department of Medical BioSciences, Nijmegen, the Netherlands
1 shared publication- Alain J. van Gool
Translational Metabolic Laboratory, Department of Laboratory Medicine, Radboud University Medical Center
1 shared publication - Aleksandr Ianevski
Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
1 shared publication - Andreas Scherer
Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
1 shared publication - Anil Kumar Giri
Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
1 shared publication - Anna Niehues
Institute for Biology and Biotechnology of Plants, University of Münster, Münster, Germany
1 shared publication
Latest Publications
- Open Access
Comprehensive multi-omics profiling of a healthy human cohort
Multi-omics approaches can offer powerful insights into personalized biomarker profiles relevant for disease diagnosis, prognosis, and therapeutics. However, separating meaningful biological variability from technical noise remains a major challenge. The EATRIS-Plus consortium analyzed blood samples from 127 healthy adults across six omics layers using twelve platforms, resulting in one of the most comprehensive multi-omics profiling datasets of healthy individuals available to date. We applied reproducible workflows to analyze and integrate these data, revealing several key findings. Sex significantly influenced all omics layers, emphasizing the importance of sex-balanced study designs. Age could be accurately predicted using epigenetic clocks, achieving high performance with our high-resolution enzymatic methylation sequencing data ( R 2 = 0.90), whereas candidate aging biomarkers were identified across all omics layers. The resulting dataset provides reference ranges in healthy individuals for abundance and variability of omics features, enabling robust power analyses, sample size estimations, and benchmarking of multi-omics integration methods. This resource can guide future biomarker discovery and personalized health research and was made FAIR-compliant and publicly available via the ClinData Portal ( https://clindata.imtm.cz ) and a Zenodo repository ( https://doi.org/10.5281/zenodo.17514796 ).
Open AccessComprehensive multi-omics profiling of a healthy human cohort
Multi-omics approaches can offer powerful insights into personalized biomarker profiles relevant for disease diagnosis, prognosis, and therapeutics. However, separating meaningful biological variability from technical noise remains a major challenge. The EATRIS-Plus consortium analyzed blood samples from 127 healthy adults across six omics layers using twelve platforms, resulting in one of the most comprehensive multi-omics profiling datasets of healthy individuals available to date. We applied reproducible workflows to analyze and integrate these data, revealing several key findings. Sex significantly influenced all omics layers, emphasizing the importance of sex-balanced study designs. Age could be accurately predicted using epigenetic clocks, achieving high performance with our high-resolution enzymatic methylation sequencing data ( R 2 = 0.90), whereas candidate aging biomarkers were identified across all omics layers. The resulting dataset provides reference ranges in healthy individuals for abundance and variability of omics features, enabling robust power analyses, sample size estimations, and benchmarking of multi-omics integration methods. This resource can guide future biomarker discovery and personalized health research and was made FAIR-compliant and publicly available via the ClinData Portal ( https://clindata.imtm.cz ) and a Zenodo repository ( https://doi.org/10.5281/zenodo.17514796 ).
- Open Access
- 19 February 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (8) , eabe4038
Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
Machine learning and single-cell data inform personalized drug combinations that selectively co-inhibit cancer cell populations.
- 19 February 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (8) , eabe4038
Open AccessPatient-tailored design for selective co-inhibition of leukemic cell subpopulations
Machine learning and single-cell data inform personalized drug combinations that selectively co-inhibit cancer cell populations.
- 1 August 1991
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 34 (2) , 153-160
Protein Kinase C Regulates MHC‐Class II Expression on Endothelial Cells
Cultured endothelial ceils (EC) were negative for class II antigen in native suite, whereas 49% of the endothelial cells began to express this antigen after 24 h of interferon‐gamma (IFN‐γ) stimulation. IFN‐γ induced relatively slowly the elevation of class II antigen on endothelial cells, since it took more than 10 h before the first signs of mRNA signal of class II were detected. Class II antigen instead began to appear during 16‐20 h after the initiation of IFN‐γ treatment. Committed step analysis revealed that IFN‐γ could not be washed away at any time point without affecting the number of class II positive cells after a 24‐h incubation period. Protein kinase C (PKC) activator phorbol‐12‐myristate‐13‐acctate (PMA) could partially mimic IFN‐γ effect in inducing class II expression on endothelial cells. PMA together with another PKC activator arachidonic acid (AA) induced class II expression on endothelial cells as welt as IFN‐γ. The crucial role of activation of PKC in the IFN‐γ induced class II expression can also be demonstrated by using PKC inhibitors in combination with IFN‐γ. PKC inhibitor H7 was able to decrease almost totally IFN‐γ induced class II induction both on the mRNA as well as on the protein level. PKC activation has often been linked to its translocation from the cytosolic compartment to the inner surface of the plasma membrane. IFN‐γ induced a transient 2.4‐fold increase in the membrane‐associated PKC in endothelial cells within 10 min after the initiation of the stimulus. Taken together these data show that IFN‐γ requires a long time before class II mRNA or protein are expressed in endothelial ceils. PKC activation is crucial for this class II induction. The regulation of class II expression occurs at transcriptional level and requires de novo protein synthesis as shown by cycloheximide inhibition.
- 1 August 1991
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 34 (2) , 153-160
Protein Kinase C Regulates MHC‐Class II Expression on Endothelial Cells
Cultured endothelial ceils (EC) were negative for class II antigen in native suite, whereas 49% of the endothelial cells began to express this antigen after 24 h of interferon‐gamma (IFN‐γ) stimulation. IFN‐γ induced relatively slowly the elevation of class II antigen on endothelial cells, since it took more than 10 h before the first signs of mRNA signal of class II were detected. Class II antigen instead began to appear during 16‐20 h after the initiation of IFN‐γ treatment. Committed step analysis revealed that IFN‐γ could not be washed away at any time point without affecting the number of class II positive cells after a 24‐h incubation period. Protein kinase C (PKC) activator phorbol‐12‐myristate‐13‐acctate (PMA) could partially mimic IFN‐γ effect in inducing class II expression on endothelial cells. PMA together with another PKC activator arachidonic acid (AA) induced class II expression on endothelial cells as welt as IFN‐γ. The crucial role of activation of PKC in the IFN‐γ induced class II expression can also be demonstrated by using PKC inhibitors in combination with IFN‐γ. PKC inhibitor H7 was able to decrease almost totally IFN‐γ induced class II induction both on the mRNA as well as on the protein level. PKC activation has often been linked to its translocation from the cytosolic compartment to the inner surface of the plasma membrane. IFN‐γ induced a transient 2.4‐fold increase in the membrane‐associated PKC in endothelial cells within 10 min after the initiation of the stimulus. Taken together these data show that IFN‐γ requires a long time before class II mRNA or protein are expressed in endothelial ceils. PKC activation is crucial for this class II induction. The regulation of class II expression occurs at transcriptional level and requires de novo protein synthesis as shown by cycloheximide inhibition.